TapImmune Inc. Share Price Other OTC
Equities
US8760333091
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
04-30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 37.17M 2.93B |
---|---|---|---|---|---|
Net income 2024 * | -17M -1.34B | Net income 2025 * | -31M -2.45B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.26
x | P/E ratio 2025 * |
-3.26
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.79% |
Latest transcript on TapImmune Inc.
Managers | Title | Age | Since |
---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 44 | 16/10/18 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/10/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Norman Eansor
CHM | Chairman | 63 | 16/10/18 |
Steven Elms
BRD | Director/Board Member | 60 | 05/08/19 |
Katharine Knobil
BRD | Director/Board Member | 60 | 07/12/21 |
1st Jan change | Capi. | |
---|---|---|
+33.35% | 49.46B | |
+1.76% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.81% | 26.61B | |
-22.30% | 18.64B | |
+7.83% | 13.16B | |
+29.52% | 12.55B | |
+24.25% | 12.1B |